Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas

Authors: Siddhartha Deb, Nicholas Jene, kConFab investigators, Stephen B Fox

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Male breast cancer (MBC) is an uncommon and relatively uncharacterised disease accounting for <1% of all breast cancers. A significant proportion occurs in families with a history of breast cancer and in particular those carrying BRCA2 mutations. Here we describe clinicopathological features and genomic BRCA1 and BRCA2 mutation status in a large cohort of familial MBCs.

Methods

Cases (n=60) included 3 BRCA1 and 25 BRCA2 mutation carries, and 32 non-BRCA1/2 (BRCAX) carriers with strong family histories of breast cancer. The cohort was examined with respect to mutation status, clinicopathological parameters including TNM staging, grade, histological subtype and intrinsic phenotype.

Results

Compared to the general population, MBC incidence was higher in all subgroups. In contrast to female breast cancer (FBC) there was greater representation of BRCA2 tumours (41.7% vs 8.3%, p=0.0008) and underrepresentation of BRCA1 tumours (5.0% vs 14.4%, p=0.0001). There was no correlation between mutation status and age of onset, disease specific survival (DSS) or other clincopathological factors. Comparison with sporadic MBC studies showed similar clinicopathological features. Prognostic variables affecting DSS included primary tumour size (p=0.003, HR:4.26 95%CI 1.63-11.11), age (p=0.002, HR:4.09 95%CI 1.65-10.12), lymphovascular (p=0.019, HR:3.25 95%CI 1.21-8.74) and perineural invasion (p=0.027, HR:2.82 95%CI 1.13-7.06). Unlike familial FBC, the histological subtypes seen in familial MBC were more similar to those seen in sporadic MBC with 46 (76.7%) pure invasive ductal carcinoma of no special type (IDC-NST), 2 (3.3%) invasive lobular carcinomas and 4 (6.7%) invasive papillary carcinoma. A further 8 (13.3%) IDC-NST had foci of micropapillary differentiation, with a strong trend for co-occurrence in BRCA2 carriers (p=0.058). Most tumours were of the luminal phenotype (89.7%), with infrequent HER2 (8.6%) and basal (1.7%) phenotype tumours seen.

Conclusion

MBC in BRCA1/2 carriers and BRCAX families is different to females. Unlike FBC, a clear BRCA1 phenotype is not seen but a possible BRCA2 phenotype of micropapillary histological subtype is suggested. Comparison with sporadic MBCs shows this to be a high-risk population making further recruitment and investigation of this cohort of value in further understanding these uncommon tumours.
Appendix
Available only for authorised users
Literature
1.
Weiss JR, Moysich KB, Swede H: Epidemiology of male breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005, 14 (1): 20-26.
2.
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, et al: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010, 28 (12): 2114-2122. 10.1200/JCO.2009.25.5729.CrossRefPubMedPubMedCentral
3.
4.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009, 59 (4): 225-249. 10.3322/caac.20006.
5.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA: a cancer journal for clinicians. 2004, 54 (1): 8-29. 10.3322/canjclin.54.1.8.
6.
Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML: Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden). Acta oncologica (Stockholm, Sweden). 2011, 50 (7): 1083-1088. 10.3109/0284186X.2011.602114.CrossRef
7.
Anderson WF, Jatoi I, Tse J, Rosenberg PS: Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010, 28 (2): 232-239. 10.1200/JCO.2009.23.8162.CrossRefPubMed
8.
Foerster R, Foerster FG, Wulff V, Schubotz B, Baaske D, Wolfgarten M, Kuhn WC, Rudlowski C: Matched-pair analysis of patients with female and male breast cancer: a comparative analysis. BMC cancer. 2011, 11: 335-10.1186/1471-2407-11-335.CrossRefPubMedPubMedCentral
9.
Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast cancer research: BCR. 2002, 4 (1): R2-10.1186/bcr419.CrossRefPubMed
10.
Evans DG, Bulman M, Young K, Gokhale D, Lalloo F: High detection rate for BRCA2 mutations in male breast cancer families from North West England. Familial cancer. 2001, 1 (3–4): 131-133.CrossRefPubMed
11.
Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001, 68 (2): 410-419. 10.1086/318181.CrossRefPubMedPubMedCentral
12.
Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, Olopade OI: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Gen. 2001, 38 (3): 159-164. 10.1136/jmg.38.3.159.CrossRef
13.
Anelli A, Anelli TF, Youngson B, Rosen PP, Borgen PI: Mutations of the p53 gene in male breast cancer. Cancer. 1995, 75 (9): 2233-2238. 10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO;2-S.CrossRefPubMed
14.
Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M: CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat. 2009, 116 (2): 397-400. 10.1007/s10549-008-0162-7.CrossRefPubMed
15.
Evans DB, Crichlow RW: Carcinoma of the male breast and Klinefelter's syndrome: is there an association?. CA: a cancer journal for clinicians. 1987, 37 (4): 246-251. 10.3322/canjclin.37.4.246.
16.
Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenbeck AR, Schatzkin A: Prospective evaluation of risk factors for male breast cancer. J Nat Cancer Inst. 2008, 100 (20): 1477-1481. 10.1093/jnci/djn329.CrossRefPubMedPubMedCentral
17.
Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer J Int du, cancer. 1993, 53 (4): 538-549. 10.1002/ijc.2910530403.CrossRef
18.
Anderson WF, Althuis MD, Brinton LA, Devesa SS: Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat. 2004, 83 (1): 77-86. 10.1023/B:BREA.0000010701.08825.2d.CrossRefPubMed
19.
Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, et al: Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res: BCR. 2006, 8 (1): R12-10.1186/bcr1377.CrossRefPubMedPubMedCentral
20.
Lum A, Le Marchand L: A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1998, 7 (8): 719-724.
21.
22.
Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, et al: Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003, 63 (7): 1449-1453.PubMed
23.
24.
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Res: an official journal of the American Association for Cancer Research. 2004, 10 (16): 5367-5374. 10.1158/1078-0432.CCR-04-0220.CrossRef
25.
Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol. 2000, 53 (8): 634-635. 10.1136/jcp.53.8.634.CrossRefPubMedPubMedCentral
26.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-145.CrossRefPubMed
27.
Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Res: an official journal of the American Association for Cancer Research. 2005, 11 (14): 5175-5180. 10.1158/1078-0432.CCR-04-2424.CrossRef
28.
Arslan UY, Oksuzoglu B, Ozdemir N, Aksoy S, Alkis N, Gok A, Kaplan MA, Gumus M, Berk V, Uncu D, et al: Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol (Northwood, London, England). 2011, 29 (2): 554-60.CrossRef
29.
Bourhafour M, Belbaraka R, Souadka A, M'Rabti H, Tijami F, Errihani H: Male breast cancer: a report of 127 cases at a Moroccan institution. BMC Res notes. 2011, 4: 219-10.1186/1756-0500-4-219.CrossRefPubMedPubMedCentral
30.
Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, et al: Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Critical reviews in oncology/hematology. 2010, 73 (3): 246-254. 10.1016/j.critrevonc.2009.04.002.CrossRefPubMed
31.
Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL: Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treatment. 2011, 126 (3): 771-778. 10.1007/s10549-010-1195-2.CrossRef
32.
Evans DG, Bulman M, Young K, Howard E, Bayliss S, Wallace A, Lalloo F: BRCA1/2 mutation analysis in male breast cancer families from North West England. Familial cancer. 2008, 7 (2): 113-117. 10.1007/s10689-007-9153-9.CrossRefPubMed
33.
Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, Ringner M, Nevanlinna H, Barkardottir RB, Borg A, et al: High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast cancer research and treatment. 2011, 129 (3): 747-760. 10.1007/s10549-010-1262-8.CrossRefPubMed
34.
Kiluk JV, Lee MC, Park CK, Meade T, Minton S, Harris E, Kim J, Laronga C: Male breast cancer: management and follow-up recommendations. The Breast J. 2011, 17 (5): 503-509. 10.1111/j.1524-4741.2011.01148.x.CrossRefPubMed
35.
Liukkonen S, Saarto T, Maenpaa H, Sjostrom-Mattson J: Male breast cancer: a survey at the Helsinki University Central Hospital during 1981–2006. Acta Oncol(Stockholm, Sweden). 2010, 49 (3): 322-327. 10.3109/02841861003591723.CrossRef
36.
Miao H, Verkooijen HM, Chia KS, Bouchardy C, Pukkala E, Laronningen S, Mellemkjaer L, Czene K, Hartman M: Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol. 2011, 29 (33): 4381-4386. 10.1200/JCO.2011.36.8902.CrossRefPubMed
37.
Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R: Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007, 109 (8): 1471-1477. 10.1002/cncr.22589.CrossRefPubMed
38.
Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, et al: BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat. 2009, 116 (3): 577-586. 10.1007/s10549-008-0194-z.CrossRefPubMed
39.
Shaaban AM, Ball GR, Brannan RA, Cserni G, Benedetto AD, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, et al: A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat. 2011, 33 (3): 949-58.
40.
Zhou FF, Xia LP, Wang X, Guo GF, Rong YM, Qiu HJ, Zhang B: Analysis of prognostic factors in male breast cancer: a report of 72 cases from a single institution. Chinese J Cancer. 2010, 29 (2): 184-188.CrossRef
41.
Loughrey M, Provan PJ, Byth K, Balleine RL: Histopathological features of 'BRCAX' familial breast cancers in the kConFab resource. Pathology. 2008, 40 (4): 352-358. 10.1080/00313020802035899.CrossRefPubMed
42.
Marchio C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, et al: Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol. 2008, 215 (4): 398-410. 10.1002/path.2368.CrossRefPubMed
43.
Johansen Taber KA, Morisy LR, Osbahr AJ, Dickinson BD: Male breast cancer: risk factors, diagnosis, and management (Review). Oncol reports. 2010, 24 (5): 1115-1120.
44.
Marchal F, Salou M, Marchal C, Lesur A, Desandes E: Men with breast cancer have same disease-specific and event-free survival as women. Annals Surg Oncol. 2009, 16 (4): 972-978. 10.1245/s10434-009-0327-6.CrossRef
45.
Ottini L, Silvestri V, Rizzolo P, Falchetti M, Zanna I, Saieva C, Masala G, Bianchi S, Manoukian S, Barile M, et al: Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012, 134 (1): 411-418. 10.1007/s10549-012-2062-0.CrossRefPubMed
46.
Tavassoli FA, Devilee P, Organization WH, Cancer IAR: Pathology and genetics of tumours of the breast and female genital organs. 2003, IARC Press, Lyon, France
47.
Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, et al: BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003, 63 (2): 342-347.PubMed
48.
Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet. 2006, 367 (9510): 595-604. 10.1016/S0140-6736(06)68226-3.CrossRefPubMed
49.
Ouriel K, Lotze MT, Hinshaw JR: Prognostic factors of carcinoma of the male breast. Surg gynecol Obstet. 1984, 159 (4): 373-376.PubMed
50.
Nassar H: Carcinomas with micropapillary morphology: clinical significance and current concepts. Adv Anatomic Pathol. 2004, 11 (6): 297-303. 10.1097/01.pap.0000138142.26882.fe.CrossRef
51.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Nat Cancer Inst. 1998, 90 (15): 1138-1145. 10.1093/jnci/90.15.1138.CrossRefPubMed
52.
Cetintas SK, Kurt M, Ozkan L, Engin K, Gokgoz S, Tasdelen I: Factors influencing axillary node metastasis in breast cancer. Tumori. 2006, 92 (5): 416-422.PubMed
53.
Duraker N, Caynak ZC, Turkoz K: Perineural invasion has no prognostic value in patients with invasive breast carcinoma. Breast (Edinburgh, Scotland). 2006, 15 (5): 629-634. 10.1016/j.breast.2005.12.003.CrossRef
54.
Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y, et al: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today. 1999, 29 (1): 16-22. 10.1007/BF02482964.CrossRefPubMed
55.
Masieri L, Lanciotti M, Nesi G, Lanzi F, Tosi N, Minervini A, Lapini A, Carini M, Serni S: Prognostic role of perineural invasion in 239 consecutive patients with pathologically organ-confined prostate cancer. Urologia internationalis. 2010, 85 (4): 396-400. 10.1159/000315491.CrossRefPubMed
56.
Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Nat Cancer Inst. 1999, 91 (15): 1310-1316. 10.1093/jnci/91.15.1310.
57.
Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, et al: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Human Genet. 1997, 61 (1): 120-128. 10.1086/513891.CrossRef
58.
Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, et al: BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clinical Cancer Res: an official journal of the American Association for Cancer Research. 2004, 10 (9): 2918-2921. 10.1158/1078-0432.CCR-03-0604.CrossRef
59.
Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ: Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Res: an official journal of the American Association for Cancer Research. 2008, 14 (10): 2953-2961. 10.1158/1078-0432.CCR-07-5237.CrossRef
Metadata
Title
Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas
Authors
Siddhartha Deb
Nicholas Jene
kConFab investigators
Stephen B Fox
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-510

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation

Research article

Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla

Research article

Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells

Research article

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death

Research article

“Iron-saturated” bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice

Research article

Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits